Issue Highlight 2015 by Lanza, F.
Issue Highlights
Issue Highlight 2015
This issue of Cytometry includes four papers dealing
with the utility of flow cytometry (FC) immunopheno-
typing, together with fine-needle aspiration cytology
(FNAC) or standard core biopsy in the diagnosis of
extra-hematological tissues obtained from patients with
different types of malignancies. These include thyroid
lymphomas, breast implant- associated anaplastic large-
cell lymphomas, intracranial meningiomas, and brain
tumors (1–4). FC studies are considered as a very useful
tool for the diagnosis and classification of T, B and NK-
cell lymphoid neoplasms, as well as of myeloid malig-
nancies (5–10). Although FC is able to provide objective
and quantitative results, even on very small samples and
within few hours, it is not routinely applied in the evalu-
ation of solid tissues suspected of lymphoma. The aim
of the retrospective studies by Stacchini et al. and
Montgomery-Goecker et al was to analyze the contribu-
tion of FC immunophenotyping to the detection of neo-
plastic cells in solid tissues suspicious for NHL (1,2). As
far as the analysis of mengioma is concerned, the DNA
ploidy and cell cycle phase determined by flow cytome-
try proved to be useful indicators for assessing biological
behaviors in meningiomas. In fact, there was a signifi-
cant difference in G0/G1 phase, S phase and mitoses frac-
tion between benign and atypical/anaplastic meningio-
mas. Based on these findings, it can be speculated that this
parameter represents tumoral grading and risk of recur-
rence in patients with meningiomas (3). With regards to
brain tumors, it has been speculated that during surgery
the differentiation between glioma versus gliosis or low-
grade astrocytomas versus glioblastoma multiforme is
important. Based on cell cycle analysis, low grade-gliomas
can be distinguished from high-grade gliomas. Moreover,
cell cycle analysis may have an additional prognostic role.
Intraoperative cell cycle analysis permits not only the char-
acterization of tumor aggressiveness but also the identifica-
tion of tumor margins during glioma surgery.
The papers published in this issue provided evidence
that FC is a reliable and precise tool for the evaluation
of immunological markers as well as of cell cycle kinetic
and proliferative activity on each tissue specimen. Fur-
thermore, it can be speculated that FC, at least in these
circumstances may avoid open biopsy, thus allowing tai-
lored treatments with clinical and survival potential
implications.
However, we do believe that only through the collab-
oration among expert practitioners expert in different
fields will it be possible to achieve a correct diagnosis of
these tissues. Overall, these manuscripts confirmed the
efficacy of the use of FC for the diagnosis of these dis-
eases, and provide objective, quantitative and rapid
results for the evaluation of solid tissues suspected for
lymphoma or other tumors (1–4).
Two further papers discuss the inclusion of novel
immunological markers in antibody panels for various leu-
kemias (11,12). This is a critical issue especially in regions
with limited resources. In that instance the minimal essen-
tial monoclonal antibody (MoAb) panel has to be
delineated by experts with the main aim to provide basic
principles and quality management guidelines (13,14).
These guidelines should be comprehensive and must
describe the minimal essential features of designing such
a flow cytometry laboratory, and they should provide a
list of equipment and supply needs and staffing features
of a laboratory’s design, setup, recommendations and
product testing services, other than discussing the basic
principles behind the most frequent procedures in FC
immunophenotyping (16–19). This is a prerequisite to
achieve the correct final diagnosis in given hematological
disorders, based on a number of basic principles includ-
ing the cost-effectiveness acceptable for services with dif-
ferent economic possibilities (14–19).
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The paper by De Vita et al. highlights the importance
of interference between monoclonal antibodies as a
source of error when analyzing multicolor flow cytome-
try data (20). The purpose of this report is to underline
a technical variable due to epitope proximity that
should be considered in the formulation of schemes of
immune cell analysis. Knowing which MoAbs may inter-
fere with the staining of other MoAbs in multicolor pan-
els should be assessed beforehand, especially when the
distance between epitopes is unknown and reagent pan-
els are aimed to explore immune cell populations for
which there are no defined reference intervals. This is a
further report highlighting the necessity of standardizing
the FC analysis in the various laboratories across the
world.
The paper by Hedley and Keeney focuses on com-
bined platelet enumeration and reticulated platelet (RP)
determination by FC, with the scope of refining previ-
ous work and gating strategies distinguishing RP from
mature platelets while incorporating accurate platelet
enumeration into the analysis (21). These authors have
shown that by combining CD41/CD61 platelet enumera-
tion with thiazole orange, the RP percentage can be cal-
culated by combining CD41/CD61 platelet enumeration
with thiazole orange. However, the accurate RP percent-
age requires an effective gating strategy, as background
fluorescence cursor placement is arbitrary. This method
for enumeration of RP percentage combined with accu-
rate platelet enumeration, particularly in the low range,
could be useful in differentiating production from con-
sumption issues in thrombocytopenia and monitoring
response to therapy (21).
Dorwal et al. reported a subject with a typical CLL
phenotype and Matutes score of five, showing the
expression of two NK-associated immunological
markers, namely CD56 and CD57 (22). These authors
speculate that this entity may represent a rare subtype
of CLL which needs to be studied more extensively for
its prognostic implications. Although there have been
multiple reports of expression of T cell associated
markers on the B-CLL cells, the expression of CD56 and
CD57 on B-CLL cells was never observed.
The paper by Whitby et al. reviewed current labora-
tory practices in FC for the enumeration of CD41 T-
lymphocyte subsets (23). These authors report the find-
ings of a survey questionnaire issued to 1587 clinical FC
laboratories to determine whether the UK NEQAS for
Leucocyte Immunophenotyping Lymphocyte Subset
External Quality Assessment (EQA) programme was suit-
able for current laboratory needs and practices, and to
assess the impact of these responses on the clinical
practice where CD41 T-lymphocyte subsets analysis is
undertaken.
The responses revealed major methodological varia-
tions between centers undertaking CD41 T lymphocyte
subset analysis. Based on these findings, it can be postu-
lated that despite the availability of international guide-
lines, a lack of concordance amongst laboratory tech-
nique still exists. Such variation could adversely impact
on patient care and clinical trial data, and therefore it is
recommended that centers undertaking flow cytometric
CD41 T-lymphocyte subsets analysis urgently review
their methodologies and normal ranges (23,24).
Levi et al. focuses on the development and implemen-
tation of a relatively novel methodology in order to opti-
mize the bio-ferrography (BF) immunomagnetic isolation
(IMI) procedure for the EGFR high positive circulating
tumor cells (CTC) application (25). I would like to
remind readers that BF allows the magnetic isolation of
target cells and tissues on a microscope slide (ferro-
gram) and their microscopic, chemical, and biological
characterization while preserving their original shape.
The results observed are quite interesting, and due to
the limited presence of CTCs in blood circulation, viable
CTCs isolation technology needs to supply a very high
recovery rate (26,27).
In the paper by DiGiuseppe et al., viSNE was used to
detect minimal residual disease (MRD) in B lymphoblas-
tic leukemia (28). viSNE is a recently developed compu-
tational tool based on the t-Distributed Stochastic Neigh-
bor Embedding (t-SNE) algorithm that has been shown
to be capable of detecting synthetic “MRD-like” popula-
tions of leukemic cells created in vitro. In vivo results
are encouraging but need to be confirmed in larger
series of patients through a comparison with a FC-based
method (29–31).
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